Clinical trial
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
NCT00272480 · Imperial College London, Other · Completed
Key facts
| NCT number | NCT00272480 |
|---|---|
| Title | Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial |
| Official title | Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial |
| Lead sponsor | Imperial College London, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | HTLV-I-associated Myelopathy |
| Intervention type | Drug |
| Interventions | Zidovudine/lamivudine, Placebos |
| Enrollment | 16 |
| Start date | Nov 8, 1999 |
| Primary completion | Jul 30, 2002 |
| Completion | Jul 30, 2002 |
| First posted | Jan 6, 2006 |
| Last update posted | Aug 25, 2021 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: